Company news
Agios Pharmaceuticals, Inc. news in 2021
Agios Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Agios to Present at 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022
December 21, 2021
Agios Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition
December 12, 2021
Agios Presents Mitapivat Data Highlighting Long-term Safety Profile and Durable Improvement in Hemoglobin and Markers of Hemolysis in Non-transfusion-dependent α- and β-Thalassemia at 63rd ASH Annual Meeting and Exposition
December 12, 2021
Agios Announces Data from Investigator-led Studies of Mitapivat in Adults with Sickle Cell Disease Demonstrating Improvements in Anemia, Hemolysis and Sickling Parameters at 63rd ASH Annual Meeting and Exposition
December 12, 2021
Agios Appoints Richa Poddar as Chief Commercial Officer
November 14, 2021
Agios to Present Broad Set of Clinical and Translational Data in Chronic Hemolytic Anemias at 63rd ASH Annual Meeting and Exposition
November 3, 2021
Agios Reports Business Highlights and Third Quarter 2021 Financial Results
November 2, 2021
Agios to Webcast Conference Call of Third Quarter 2021 Financial Results on Nov. 3, 2021
October 20, 2021
Agios To Present at September Investor Conferences
August 29, 2021
Agios Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
August 16, 2021
Agios Reports Business Highlights and Second Quarter 2021 Financial Results
July 28, 2021
Agios to Webcast Conference Call of Second Quarter 2021 Financial Results on July 29, 2021
July 14, 2021
Agios Submits Marketing Authorisation Application to European Medicines Agency for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
June 27, 2021
Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency
June 21, 2021
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
June 20, 2021
Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress
June 10, 2021
Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress
June 10, 2021
Agios to Present Updated Data from Clinical Trials of Mitapivat in Pyruvate Kinase Deficiency and Thalassemia in Oral Presentations at the European Hematology Association Annual Congress
May 11, 2021
Agios Reports Business Highlights and First Quarter 2021 Financial Results
April 28, 2021
Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021
April 14, 2021
Agios Announces Closing of Oncology Business Sale to Servier
March 31, 2021
Agios Shareholders Approve Sale of Oncology Business to Servier
March 24, 2021
Agios Sponsors Program Promoting Health Literacy for Patients with Sickle Cell Disease
March 17, 2021
Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
February 28, 2021
Agios Recognizes 14th Annual Rare Disease Day and Raises Awareness of Unmet Needs in Rare Hemolytic Anemias
February 25, 2021
Agios Reports Fourth Quarter and Full Year 2020 Financial Results
February 24, 2021
Agios to Present at March Investor Conferences
February 22, 2021
Agios to Webcast Conference Call of Fourth Quarter and Year End 2020 Financial Results on February 25, 2021
February 10, 2021
Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused
January 25, 2021
Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
January 16, 2021
Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
January 10, 2021
Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
January 4, 2021
Calls in 2021
- Agios Pharmaceuticals (NASDAQ:AGIO) Q3 2021 Earnings Call
Nov 3, 2021
Transcript - Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2021 Earnings Call
Jul 29, 2021
Transcript - Agios Pharmaceuticals (NASDAQ:AGIO) Q1 2021 Earnings Call
Apr 29, 2021
Transcript - Agios Pharmaceuticals (NASDAQ:AGIO) Q4 2020 Earnings Call
Feb 25, 2021
Transcript
Decks in 2021
- 39th Annual J.P. Morgan Healthcare Conference 2021
Conference · 24 slides · Jan 12, 2021